Search Results
Your search for ,waY matches 3910 pages
Showing 1551 - 1600Solving the Mystery of Why Colorectal Cancer Is on the Rise in Young Adults
Excluding skin cancer, colorectal cancer is the third most prevalent and lethal cancer among both men and women in the United States.1 Although the risk of developing colorectal cancer increases with age—more than 90% of cases occur in people aged 50 or older2—recent research shows that the...
An ASCO Survey, Hope, and Conventional Therapies
HOW DO YOU respond when patients with a good prognosis want to delay chemotherapy to try an anticancer diet for a few months or visit an unregulated clinic for unproven therapies? I’m asking because of an alarming finding of ASCO’s 2018 National Cancer Opinion Survey: “Nearly 4 in 10 Americans...
Chemotherapy and/or Hormonal Agents: Differing Perspectives
WHEN ASKED which treatment to start with—docetaxel or enzalutamide, Dr. Sweeney said, “Patients fit for chemotherapy with high-volume disease can receive chemotherapy [docetaxel] and come back to these newer hormonal treatments or start with anyone of the hormonal options. Choosing among the newer...
ENZAMET Trial Shows Enzalutamide Improves Overall Survival in Hormone-Sensitive Metastatic Prostate Cancer
Agents that improve survival in metastatic castration-resistant prostate cancer when added to background androgen-deprivation therapy (ADT) are showing success in treating metastatic prostate cancer earlier while it is still hormone-sensitive. These agents include docetaxel (chemotherapy) and...
Transitioning From Healthy Physician to Patient With Cancer
As you probably already know, physicians do not make the best patients. When I began experiencing the early signs of Hodgkin lymphoma, in 2007, including a persistent cough, unusual fatigue, and pruritus, I self-diagnosed allergic rhinitis and began treatment with intranasal corticosteroids....
Ask Your Patients About Complementary and Alternative Therapies
The most common reason that patients with cancer do not tell their physicians about using complementary and alternative medicines is that their physicians do not ask, according to a nationwide survey.1 Among 3,118 survey participants who reported a history of cancer, 1,023 (33.3%) had used a...
Are Your Patients Using Complementary and Alternative Therapies? You Might Not Know If You Don’t Ask
Nearly one-third of patients with cancer who reported that they used complementary and alternative therapies in a nationwide survey did not tell their physicians about the use of those therapies, and the most frequently cited reason for not telling their physicians was that their physicians did...
Denosumab Prevents Neither Breast Cancer Relapse Nor Death
The recently published report of Austrian Breast and Colorectal Cancer Study Group’s Study 18 (ABCSG-18)1 for the secondary endpoint of disease-free survival suggests that denosumab given in a low dose of 60 mg subcutaneously every 6 months during aromatase inhibitor adjuvant therapy is...
Immune Response to HPV16-Driven Tumorigenesis May Be Detectable Before Clinical Diagnosis of Oropharyngeal Squamous Cell Carcinoma
An international group of researchers has found that antibodies to the human papillomavirus type 16 (HPV16) may develop in the body between 6 to 40 years prior to a clinical diagnosis of oropharyngeal squamous cell carcinoma, and their presence indicates a strong increased risk of the disease....
Personalized Assay May Aid in Determining Risk of Recurrence of Triple-Negative Breast Cancer
Sixty percent of patients with triple-negative breast cancer will survive more than 5 years without disease after standard treatment, but 4 out of 10 women will have a rapid recurrence of the disease. There are currently no clinical tests to assess an individual patient’s prognosis, so all...
What We Remember: From D-Day to Cancer Care
I RECENTLY returned from Normandy, France, where my wife and I attended events honoring the 75th Anniversary of D-Day and the millions, including close friends and family, who fought and died in the Second World War. My wife and a journalist from Los Angeles laid a wreath on Omaha Beach in honor of ...
Selected Abstracts From the 2019 ASCO Annual Meeting
To complement The ASCO Post’s comprehensive coverage of the 2019 ASCO Annual Meeting, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens for plasma cell dyscrasias, particularly multiple myeloma. For full details of these study abstracts, visit ...
New Content Collection in JCO Clinical Cancer Informatics Delves Into the Field of Mathematical Oncology
Mathematics, modeling, and simulation to study cancer are topics covered in a new special series in JCO Clinical Cancer Informatics (JCO CCI). On April 24, JCO CCI published its fourth special collection of articles, “Mathematical Oncology,” which showcases the current state of the field and new...
KEYNOTE-001 Shows Long-Term Survival Benefit With Pembrolizumab in Advanced NSCLC
Before the introduction of immunotherapy with checkpoint inhibitors, the 5-year life expectancy for patients with advanced non–small cell lung cancer (NSCLC) was 5.5%. This dismal outlook has changed. Treatment with the immune checkpoint inhibitor pembrolizumab dramatically improved overall...
Expert Point of View: Harold Burstein, MD, PhD, FASCO, and Jame Abraham, MD, FACP
Harold Burstein, MD, PhD, FASCO, Associate Professor of Medicine at Dana-Farber Cancer Institute, Boston, and Jame Abraham, MD, FACP, Director of the Breast Oncology Program at Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program, commented on what...
MONALEESA-7 Shows Overall Survival Benefit for Ribociclib/Endocrine Therapy
The first statistically significant overall survival benefit has been shown for a cyclin-dependent kinase (CDK) 4/6 inhibitor plus endocrine therapy as first-line treatment of advanced breast cancer. The results are from the phase III MONALEESA-7 trial, which evaluated ribociclib plus endocrine...
2019 ASCO: Rituximab, Lenalidomide, and Ibrutinib Prior to Chemotherapy in DLBCL
Results of the phase II Smart Start trial revealed that combination targeted therapy consisting of rituximab, lenalidomide, and ibrutinib had an 84.6% overall response rate (ORR) and 38.5% complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a...
An Extended Family With Many Physicians Inspired a Career in Oncology
Head and neck cancer specialist Cristina P. Rodriguez, MD, was born and reared in Manila, the capital and largest city in the Philippines. “I grew up on the campus of the University of the Philippines, as both my parents were professors. I am one of three girls, and there was quite a bit of stress ...
Arti Hurria, MD, FASCO
The oncology community was deeply saddened by the untimely passing of Arti Hurria, MD, FASCO, a nationally regarded expert and advocate for elderly patients with cancer. Dr. Hurria died on November 7, 2018, in a traffic accident. At the time of her tragic death, Dr. Hurria was Director of the City...
An Aspiring Musician Changes Course and Becomes a Breast Cancer Specialist Who Makes Music
Internationally renowned breast cancer expert, Larry Norton, MD, FASCO, spent his formative years in a Long Island town that rubbed shoulders with the border of New York City. Making music was Dr. Norton’s first passion and a cheap subway ride landed him in Greenwich Village, the Holy Grail of the ...
Ahead of the Curve, Breast Cancer Specialist Advocates Prevention Through Exercise and Lifestyle
Breast cancer specialist Julie Gralow, MD, FASCO, Director, Breast Medical Oncology, Seattle Cancer Care Alliance, has a straightforward philosophy about her career: “Cancer is about living, not dying. I enjoy helping my patients with breast cancer take control of their health through leading-edge ...
Never Forgetting His Roots Helps Surgical Oncologist Better Connect With His Patients
Raja M. Flores, MD, grew up in New York’s Meatpacking District, a rough West Side neighborhood, light years before its gentrification into a hip commercial area, home to the Whitney Museum of American Art, high-end designer clothing stores and chic bars, and a stretch of the High Line (an...
From the Lab to the Clinic to the Sea: Balancing a Challenging Career
Internationally recognized breast cancer expert Lisa A. Carey, MD, FASCO, was born in New Jersey and moved to Montreal, where she attended an all-girls school (Miss Edgar’s and Miss Cramp’s School for Girls) until age 8. When she was 9 years old, her father’s business ventures took the family back ...
A Brilliant Career in Oncology Decided on a Coin Toss
Rajendra Achyut Badwe, MBBS, MS, was born and reared in the sprawling city of Mumbai, the most populous city in India. “My grandmother was a matron in an infectious disease hospital. At that time, smallpox was a serious issue, and the patient care challenges were momentous. She taught me the value...
Radiation Oncologist Lori J. Pierce, MD, FASCO, FASTRO, Enjoys Balancing Administrative and Clinical Roles
Lori J. Pierce, MD, FASCO, FASTRO, grew up in Washington, DC, and moved with her family to Philadelphia while in high school. She still considers the fast-paced DC–Philadelphia corridor her home, but her passion for a career in medicine, in part, took seed in a small town located in North...
Breast Cancer Specialist Focuses on Educational Side of Oncology, Connecting Patients With Cancer Around the World
Internationally renowned breast cancer specialist Daniel A. Vorobiof, MD, was born in Santa Fe, Argentina, a province in the northeastern region of the country that is prone to catastrophic flooding. Asked about any early influences in his desire to pursue a career in medicine, Dr. Vorobiof...
James P. Allison, PhD
James P. Allison, PhD, is Chair of Immunology and Executive Director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center in Houston. In 2018, Dr. Allison received the 2018 Nobel Prize in Physiology or Medicine, with Tasuku Honjo, MD, PhD, for launching an effective...
Cancer Researcher Continues to Push the Envelope in Immunotherapy to Help Patients Live Longer
Nationally regarded cancer immunologist Padmanee Sharma, MD, PhD, was born and reared in Georgetown, Guyana, on South America’s North Atlantic coast, noted for being the only South American country in which English is the official language. Her parents were descendants of indentured immigrants...
AYA Survivors Should Be Allowed to Participate in Adult Clinical Trials
When strangers ask me how many children I have, I’m not quite sure how to respond. Do I still have four children even though one has died? A year and a half after my son Brent’s death, at the age of 18, from complications of acute myeloid leukemia (AML), I’m still struggling with knowing the...
Lifestyle Modifications and Screening of Patients at High Risk Can Reduce Deaths From Pancreatic Cancer
After disclosing that he had been diagnosed with stage IV pancreatic cancer, Alex Trebek, longtime host of the popular television game show Jeopardy!, vowed that he would beat the disease despite the low associated survival rate. His statement has brought pancreatic cancer back into the public...
Rookie
His steps generated a low rumble that propagated through the floor like a tsunami, flowed up through my desk, and ended as tiny waves visible through the clear plastic of my water bottle. His custom Lucchese ostrich boots made a distinctive clicking sound as they rhythmically struck the tile floor, ...
Debating the Role of Opioids in the Management of Chronic Cancer Pain
Despite the increasing public awareness of the danger of the overuse of prescription opioids, drug overdose deaths continue to rise in the United States. According to the Centers for Disease Control and Prevention (CDC), from 1999 to 2017, nearly 400,000 people died of an overdose involving...
Otis W. Brawley, MD, MACP, FASCO: Doctor, Policy Advocate, Writer, and Champion of the Underserved
In this installment of Living a Full Life, guest editor Jame Abraham, MD, FACP, spoke with Otis W. Brawley, MD, MACP, FASCO, a global leader in cancer research and health disparities. Dr. Brawley, who served as Chief Medical and Scientific Officer for the American Cancer Society (ACS) and...
Barriers to Cervical Cancer Screening Among HIV-Infected Women in Tanzania
Population screening programs and the advent of human papillomavirus (HPV) vaccination have made cervical cancer largely a preventable disease. Despite these advances, cervical cancer remains a leading cause of cancer death for women in low- and middle-income countries. A recent study identified...
Ghanaian Oncologist Yehoda M. Martei, MD, Seeks Ways to Improve Outcomes in the Developing World
Breast cancer remains the most commonly diagnosed cancer among women globally. Due to a lack of early interventions, most women in low- and middle-income countries have advanced disease at the time of diagnosis, conferring a grim prognosis. Yehoda M. Martei, MD, of the Department of Medicine,...
Uniting the Global Cancer Community to Reduce Deaths From Noncommunicable Diseases
It has been well documented that noncommunicable diseases, including cancer, cardiovascular disease, and diabetes, now pose the greatest health threat to people living in low- and middle-income countries, surpassing infectious diseases like HIV/AIDS as the leading cause of death and disability.1...
St. Jude Children’s Research Hospital and WHO Join Forces to Improve Childhood Cancer Survival Worldwide
A report by the International Agency for Research on Cancer (IARC) based on data from more than 100 cancer registries in 68 countries shows that from 2001 to 2010, the occurrence of childhood cancer worldwide was 13% more common than in the 1980s.1 In addition, the report’s findings showcase stark...
How Cancer Affects Adolescents and Young Adults
The statistics are alarming: according to the National Cancer Institute (NCI), about 70,000 adolescents and young adults (AYAs) are diagnosed with cancer each year1—a recent report by the University of California put that figure at 87,000.2 Although overall cancer survival rates continue to improve ...
Combination Immunotherapy With Lenalidomide Plus Rituximab in Indolent NHL: Time to Replace Rituximab Monotherapy?
With increasing knowledge on the key role of the tumor microenvironment in lymphomagenesis, treatments for indolent B-cell lymphoma, especially follicular lymphoma, are mechanistically moving toward a more immunomodulatory approach. Chemotherapy-free regimens are an attractive alternative to...
Prolonged Exposure to Ibrutinib May Increase Effectiveness of CAR T-Cell Therapy in Patients With CLL
Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable efficacy in the treatment of certain hematologic malignancies, including several types of large B-cell non-Hodgkin lymphomas (NHLs) and acute lymphoblastic leukemia (ALL). The U.S. Food and Drug Administration (FDA) has approved...
Introducing CancerLinQ® 2.0 and a New Era in Precision Oncology
In just 5 years since its launch in 2014, CancerLinQ®, ASCO’s big-data, rapid-learning, health information technology platform, has grown from 37 vanguard oncology practices to 58 participating practices in 2016 to 100 diverse oncology practices nationwide this year. CancerLinQ...
Targeted Brachytherapy May Improve Outcomes in Recurrent Brain Tumors
For recurrent, previously irradiated brain tumors, innovative treatment with surgically targeted brachytherapy yielded good local control and overall survival, as compared to historic controls, neurosurgeons reported at the 2019 Annual Scientific Meeting of the American Association of Neurological...
Factors Associated With Major Adverse Cardiovascular Events in Survivors of Colorectal Cancer
Colorectal cancer survivors’ risk for heart attack—five times that of the average person—may be linked to the amount of fat stored within the abdomen and abdominal muscles, not to body mass index (BMI), according to a new study of 2,800 colon cancer survivor health outcomes...
Members of Congress Express Support for Cancer Policy Priorities During Capitol Hill Event
ASCO and the American Cancer Society Cancer Action Network (ACS CAN) hosted a reception on Capitol Hill for Members of Congress and their staff to underscore the two organizations’ shared policy priorities to improve research and cancer care delivery for patients and survivors. During the...
Locoregional Recurrence After Mastectomy for DCIS More Common Among Younger Women, Study Finds
Young age appears to be a risk factor for locoregional recurrence after mastectomy for ductal carcinoma in situ (DCIS) with or without microinvasion, according to data presented at the 2019 Society of Surgical Oncology Annual Cancer Symposium.1 The retrospective analysis of more than 3,000 cases...
NCCN Clinical Practice Guidelines in Oncology: 2019 Updates
In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®), covering eight tumor types. NCCN Guidelines are now published for more than 70 tumor types and topics. Some of the key updates for 2019 were presented...
Expert Point of View: Armin Shahrokni, MD
“Older and frail adults with cancer are the types of patients we deal with every day,” said Armin Shahrokni, MD, a geriatric oncologist at Memorial Sloan Kettering Cancer Center in New York. “The GO2 study is important, and I suspect it will be practice-changing,” he predicted. Older and frail...
Study Finds New Candidate Susceptibility Genes for High-Grade Serous Ovarian Cancer
A team of researchers have identified 34 genes that are associated with an increased risk for developing the earliest stages of ovarian cancer. The findings, published by Gusev et al in Nature Genetics, may help identify women who are at highest risk of developing ovarian cancer and pave the way...
For Your Patients: New ASCO Answers Fact Sheet on Immunotherapy Side Effects
IMMUNOTHERAPY IS changing the way that cancer is being treated, but the understanding of the side effects of these treatments is still a developing field. The ASCO Answers “Side Effects of Immunotherapy” fact sheet helps patients learn about which side effects may arise from treatment with...
Expert Point of View: Namrata Vijayvergia, MD
NAMRATA VIJAYVERGIA, MD, of Fox Chase Cancer Center, Philadelphia, commented on this study. “This is an important study because it is done in a rare tumor type; not a lot of clinical trials are conducted in this disease. Recently, three other studies of single-agent therapy with checkpoint...
